All News Virios Therapeutics, Inc.

Equities

VIRI

US92829J1043

Market Closed - Nasdaq Other stock markets 01:30:00 2024-07-03 pm EDT			5-day change	1st Jan Change
0.2401 ^USD	+2.61%		+0.63%	-58.24%

Jun. 20	Maxim Initiates Virios Therapeutics at Buy Rating With $1 Price Target	MT
May. 20	Top Midday Decliners	MT

All News

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Maxim Initiates Virios Therapeutics at Buy Rating With $1 Price Target	Jun. 20	MT
Virios Therapeutics Announces Closing of $1.7 Million Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b Study	May. 22	AQ
Top Midday Decliners	May. 20	MT
Virios Therapeutics Announces Proposed Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b Study	May. 20	AQ
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Ahead of NVIDIA Earnings due Wednesday	May. 20	MT
Virios Therapeutics Prices $1.7 Million Common Stock Offering	May. 20	MT
Virios Therapeutics Announces Pricing of $1.7 Million Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b Study	May. 19	AQ
Virios Therapeutics Announces Proposed Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b Study	May. 17	AQ
Virios Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update	May. 10	AQ
Transcript : Virios Therapeutics, Inc., Q1 2024 Earnings Call, May 09, 2024	May. 09
Virios Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 09	CI
Virios Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update	May. 09	AQ
Virios Therapeutics to Report First Quarter 2024 Financial Results on Thursday, May 9, 2024	May. 02	AQ
Virios Therapeutics Announces Publication of International Patent for IMC-2 Covering Antiviral Treatment of Long-COVID	Mar. 26	AQ
Virios Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results	Mar. 01	AQ
Virios Therapeutics Issues Shareholder Letter Highlighting Corporate Progress and Key Upcoming Milestones	Feb. 29	AQ
Virios Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 29	CI
Virios Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results	Feb. 29	AQ
Virios Therapeutics Issues Shareholder Letter Highlighting Corporate Progress and Key Upcoming Milestones	Feb. 28	AQ
Virios Therapeutics Announces Plans to Advance Development of IMC-2 as Treatment for Symptoms Associated with Long-COVID	Jan. 22	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

All News Virios Therapeutics, Inc.

Equities

VIRI

US92829J1043

All News

Filters